Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Daniel M. Hartung, PharmD, MPH
Advertisement
Articles by Daniel M. Hartung, PharmD, MPH
Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
Cardiology Prices Vary Widely by Insurer and State
3
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
4
Active US Drug Shortages Rise for Third Straight Quarter
5